Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Artiva Biotherapeutics Inc (ARTV)

39 + Investors. Track Smart Money conviction in ARTV. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +5
Streak
1Q ▲
Buyers last Q
42%

Smart Money Signals — ARTV

Based on 39 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 1 quarter in a row

last 6Q
For 1 consecutive quarter, more hedge funds added ARTV than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🔻

Below peak — only 68% of 3.0Y high

68% of all-time peak
Only 39 funds hold ARTV today versus a peak of 57 funds at 2024 Q4 — just 68% of the maximum. Low institutional ownership can mean the stock is out of favor, but it also means there's a large pool of potential buyers if sentiment turns.
📉

Outflows — 25% fewer funds vs a year ago

fund count last 6Q
13 fewer hedge funds hold ARTV compared to a year ago (-25% decline). When institutions consistently reduce their exposure, it's worth exploring the underlying fundamental reasons driving them away.
🟠

More sellers than buyers — 42% buying

14 buying19 selling
Last quarter: 19 funds reduced or exited vs 14 that bought or added. When more than half of active funds are selling, it's a caution flag — especially if the stock price hasn't moved down yet.
📈

More new buyers each quarter (+6 vs last Q)

new funds entering per quarter
Funds opening a new ARTV position: 12 → 5 → 6 → 12. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.
🔄

Mostly new holders — 36% entered in last year

■ 8% conviction (2yr+) ■ 56% medium ■ 36% new
Only 3 funds (8%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.
💰

Price up while funds trimmed (+49% value, -1% shares)

Value
+49%
Shares
0%
Last quarter: total value of institutional ARTV holdings rose +49% even though funds reduced share count by 1%. The stock price increased enough to offset the selling. Institutions are quietly trimming into price strength — watch for rotation.
➡️

Steady discovery — ~12 new funds/quarter

3 → 12 → 5 → 6 → 12 new funds/Q
New funds entering each quarter: 12 → 5 → 6 → 12. Consistent flow of new institutional buyers without clear acceleration or slowdown.
📊

Mixed cohorts — 8% veterans, 44% new entrants

■ 8% veterans ■ 49% 1-2yr ■ 44% new
Of 39 current holders: 3 (8%) held 2+ years, 19 held 1–2 years, 17 (44%) entered in the past year. Balanced distribution — some institutional memory, some recent momentum buyers.
📋

Smaller funds dominant — 7% AUM from top-100

7% from top-100 AUM funds
16 of 39 holders rank in the top 100 by AUM, but together hold only 7% of total institutional value. The stock is held primarily by smaller and mid-sized funds.
2.7
out of 10
Low Exit Risk
Exit risk score 2.7/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — ARTV

In 2026 Q1, 14 hedge funds were net buyers of ARTV (12 opened a new position, 2 added to an existing one), while 19 reduced or exited (12 trimmed, 7 sold completely) — a 42% buyer ratio, indicating roughly balanced activity. Net fund flow last quarter: +5 funds (more new holders than closures). Total institutional holders: 39.

Hedge Fund Ownership: ARTV

How many hedge funds hold ARTV — quarterly history vs. share price
Quarterly hedge fund ownership of ARTV vs. share price

Market Analysis: ARTV

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: ARTV

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Artiva Biotherapeutics Inc (ARTV) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much ARTV has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 81d ago
ARTV
+52.5%
XLV
+2.1%

ARTV outperformed XLV by +50.4% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 36d ago
ARTV
+0.4%
XLV
+3.2%

Since the filing became public, ARTV outperformed XLV by -2.8% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

4 top-rated funds 1 high-conviction
Consensus
3.0
/ 10
breadth
×
Elite
1.2
/ 10
conviction
Hedge Fund Positioning: ARTV
39 + Investors

Track Smart Money conviction in ARTV. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 39 34 14.71%
13F Shares 17M 17M -0.72%
Total Value $108M $73M 49.05%
New Positions 12 6 +6
Increased Positions 2 4 -2
Closed Positions 7 11 -4
Reduced Positions 12 15 -3
Total Calls 0 0 -
Total Puts 0 0 -
PUT/CALL Ratio 0.0 0.0 Bullish

Statistics: ARTV

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

39 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in ARTV. Verified SEC 13F-HR filings.

QUARTER:
Top 25 ARTV holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 5AM Venture Management, LLC 4.21% 2,353,304 $15.2M
2 Revelation Capital Management, LLC 2.86% 299,311 $1.9M
3 venBio Partners LLC 1.22% 531,337 $3.4M
4 Ra Capital Management, L.P. 0.67% 9,853,302 $63.5M
5 Propel Bio Management, LLC 0.60% 146,369 $950K
6 Venrock Adviser, LLC 0.39% 1,609,569 $10.4M
7 Velan Capital Investment Management LP 0.10% 25,000 $161K
8 Bridgeway Capital Management, LLC 0.00% 35,000 $225K
9 Bailard, INC. 0.00% 20,700 $133K
10 Simplify Asset Management Inc. 0.00% 23,230 $150K
11 XTX Topco Ltd 0.00% 20,270 $131K
12 Mark Sheptoff Financial Planning, LLC 0.00% 400 $4K
13 Alyeska Investment Group, L.P. 0.00% 100,000 $644K
14 Franklin Resources Inc 0.00% 520,327 $3.4M
15 Renaissance Technologies LLC 0.00% 80,038 $515K
16 Sanctuary Advisors, LLC 0.00% 21,581 $139K
17 Panagora Asset Management Inc 0.00% 30,702 $198K
18 Two Sigma Investments, LP 0.00% 115,041 $741K
19 OMERS ADMINISTRATION Corp 0.00% 11,400 $73K
20 Millennium Management LLC 0.00% 123,270 $794K
21 Wellington Management Group LLP 0.00% 194,108 $1.3M
22 Vanguard Fiduciary Trust Co 0.00% 32,810 $211K
23 Russell Investments Group, Ltd. 0.00% 5,491 $35K
24 Vanguard Capital Management LLC 0.00% 207,686 $1.3M
25 Jane Street Group, LLC 0.00% 39,496 $254K
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Artiva Biotherapeutics Inc (ARTV)

What does the Smart Money Trend signal show for ARTV?

Buying streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds added ARTV than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for ARTV?

More sellers than buyers — 42% buying: Last quarter: 19 funds reduced or exited vs 14 that bought or added. When more than half of active funds are selling, it's a caution flag — especially if the stock price hasn't moved down yet.

What is the fund quality score for ARTV holders?

Smaller funds dominant — 7% AUM from top-100: 16 of 39 holders rank in the top 100 by AUM, but together hold only 7% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

How long have hedge funds held ARTV?

Mostly new holders — 36% entered in last year: Only 3 funds (8%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

Is it too late to buy Artiva Biotherapeutics Inc (ARTV) following the 2026 Q1 hedge fund 13F filings?

As of today, ARTV has moved +0.4% since the 2026 Q1 13F filing date (May 15, 2026), compared to +3.2% for the XLV sector ETF — an outperformance of -2.8%. Since the quarter end (March 31, 2026), ARTV has gained +52.5% vs +2.1% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →